Orlistat is used for the treatment of obesity.The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body mass.After orlistat was stopped, a significant number of subjects regained weight—up to 35% of the weight they had lost. The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%).Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively). 

Guanlang is specialized in pharmaceutical intermediates, veterinary drug intermediates and dyes intermediates,such as phenylacetamide, dimethylamine hcl, benzyl chloride etc., Crovell also supply various industrial chemicals for customers, such as citric acid,potassium chloride etc.

After ten years development,Crovell has become a Diversified development company,not only involves in chemicals, but also real estate ,clothes ,agricultural products and so on.

So far, Crovell has business in more than 35 countries,most big customers come from europe and America, because among the suppliers in china,Crovell can always make the product quality best, some of the products from Crovell can reach the purity of 99.9+, such as 2-phenylacetamide. This is the important reason for customers who choosing Crovell.

Details

Orlistat is used for the treatment of obesity.The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body mass.After orlistat was stopped, a significant number of subjects regained weight—up to 35% of the weight they had lost. The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%).Long-term use of orlistat also leads to a modest reduction in blood pressure